

Mar. 13. 2008 12:35PM Farsight Patents (650)-679-9596
01/25/2008 14:23 6507809030

No. 0030 P. 7/11
FARSIGHT/HIGH TECHNI

PAGE 04/08

RECEIVED
CENTRAL FAX CENTER

RECEIVED
CENTRAL FAX CENTER


JAN 25 2008

Intarcia Dkt No. ALE 054.11
USSN: 09/976,228
PATENT

MAR 12 2008

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.


Signature

1/25/2008
Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: KLEINER, Lothar, et al.	Confirmation No.: 9517
Serial No.: 09/976,228	Art Unit: 1616
Filing Date: 12 October 2001	Examiner: Brown, C.A.
Title: RATE CONTROLLING MEMBRANES FOR CONTROLLED DRUG DELIVERY DEVICES	

REVOCATION AND SUBSTITUTE POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified patent application is a continuation of U.S. Patent Application No. 09/213,213, filed 12-17-1998, now U.S. Patent No. 6,375,978, which claims priority from U.S. Provisional Patent Application No. 60/068,377, filed 12-22-1997, now expired.

The undersigned has reviewed all the documents in the chain of title pursuant to 37 C.F.R. §3.73, and to the best of the undersigned's knowledge, Intarcia Therapeutics, Inc., is the assignee of the entire right, title, and interest in this application, specifically: the assignment recorded on 3/5/1998 at Reel/Frame 9023/0239, and the assignment recorded on 12/13/2007 at Reel/Frame 020252/0143.

Intarcia Therapeutics, Inc., hereby revokes all powers of attorney previously given and hereby appoints the following attorney and agent to prosecute this application and to make alterations and amendments therein. Each of the following attorney and agent has full power of substitution and revocation:

Barbara G. McClung (Registration No. 33,113) Gary R. Fabian (Registration No. 33,875)

1

PAGE 4/8 * RCVD AT 1/25/2008 5:36:35 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/9 * DNIS:2738300 * CSID:6507809030 * DURATION (mm:ss):01:38

PAGE 7/11 * RCVD AT 3/13/2008 4:35:40 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-4/18 * DNIS:2738300 * CSID:650 679 9596 * DURATION (mm:ss):03:12

Mar. 13, 2008 12:35PM Farsight Patents (650)-679-9596
01/25/2008 14:23 6507809030 FARSIGHT/HIGH TECHNI

No. 0030 P. 8/11
PAGE 05/08

RECEIVED
CENTRAL FAX CENTER Intarcia Dkt No. ALE 054.11
JAN 25 2008 USSN: 09/976,228
PATENT

Please direct all future correspondences in connection with this application to:

Customer Number: 000074866

Barbara G. McClung, Esq.
Vice President, General Counsel and Corporate Secretary
Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608
Phone: (510) 652-2600
Fax: (510) 652-2657


No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number ALE 054.11) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,

Dated: 1/17/08

By:


Barbara G. McClung, Esq.
Vice President, General Counsel and
Corporate Secretary
Intarcia Therapeutics, Inc.
Registration No. 33,113

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608
Phone: (510) 652-2600
Fax: (510) 652-2657